[11C]Gefitinib ([11C]Iressa): Radiosynthesis, In Vitro uptake, and In Vivo imaging of intact murine fibrosarcoma

Molecular Imaging and Biology

Volumn 12, Issue 2, 2010, Pages 181-191

  Zhang, Ming Rong ^a   Kumata, Katsushi ^a   Hatori, Akiko ^a   Takai, Nobuhiko ^a   Toyohara, Jun ^b   Yamasaki, Tomoteru ^a   Yanamoto, Kazuhiko ^a   Yui, Joji ^a   Kawamura, Kazunori ^a   Koike, Sachiko ^a   Ando, Koichi ^a   Suzuki, Kazutoshi ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Carbon 11; Carbon ion radiotherapy; CIRT; Fibrosarcoma; Gefitinib; Iressa; Positron emission tomography

Indexed keywords

CARBON 11; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; CARBON; DIAGNOSTIC AGENT; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG LIVER LEVEL; DRUG STABILITY; DRUG STRUCTURE; DRUG TUMOR LEVEL; DRUG UPTAKE; FIBROSARCOMA; HUMAN; HUMAN CELL; IMAGE DISPLAY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LEUKEMIA CELL LINE; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; SQUAMOUS CELL CARCINOMA; ANIMAL; CHEMISTRY; METHODOLOGY; MOLECULAR IMAGING; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANTIRHEA; MURINAE; MUS;

ANIMALS; CARBON RADIOISOTOPES; CELL LINE, TUMOR; FIBROSARCOMA; HUMANS; MALE; MICE; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; QUINAZOLINES; TISSUE DISTRIBUTION;

EID: 77953534901     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0265-5     Document Type: Article

References (38)

1. Khazaie K, Schirrmacher V, Lichtner RB (1993) EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 12:255-274
2. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8:1197-1206
3. Boschelli DH (2002) 4-Anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors. Curr Top Med Chem 2:1051-1063
4. Raymond E, Faivre S, Armand JP (2000) Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 (suppl 1):15-23
5. Ciardiello F, Caputo R, Bianco R et al (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-1465 (Pubitemid 32708703)
6. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL (2001) Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-over-expressing breast cancer cells in vitro and in vivo. Cancer Res 61:8887-8895 (Pubitemid 34013905)
7. Wakeling AE, Guy SP, Woodburn JR et al (2002) ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62:5749-5754
8. Anido J, Matar P, Albanell J et al (2003) ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9:1274-1283
9. Bellomi M, Petralia G, Sonzogni A, Zampino MG, Rocca A (2007) CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology 244:486-493
10. Søvik A, Kippenes SH, Bruland ØS, Rune OD, Malinen E (2008) DCEMRI monitoring of canine tumors during fractionated radiotherapy. Acta Oncol 47:1249-1256
11. Mikhaeel NG (2006) Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. Eur J Nucl Med Mol Imaging 33(Suppl 1):22-26
12. Molthoff CF, Klabbers BM, Berkhof J et al (2007) Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2′-deoxy-2′-[18F]fluoro-D-glucose (FDG) and 3′-[18F] fluoro-3′-deoxythymidine (FLT). Mol Imaging Biol 9:340-347
13. Van de Wiele C, Lahorte C, Oyen W et al (2003) Nuclear medicine imaging to predict response to radiotherapy: a review. Int J Radiat Oncol Biol Phys 55:5-15
14. Riesterer O, Milas L, Ang KK (2007) Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J Clin Oncol 25:4075-4083
15. Fredriksson A, Stone-Elander S (2003) PET screening of anticancer drugs. A faster route to drug/target evaluations in vivo. Methods Mol Med 85:279-294
16. Bading JR, Shields AF (2008) Imaging of cell proliferation: status and prospects. J Nucl Med 49(Suppl 2):64S-80S
17. Ishikawa H, Tsuji H, Kamada T et al (2006) Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. Int J Radiat Oncol Biol Phys 66:1084-1091
18. Tsuji H, Mizoe J, Kamada T et al (2007) Clinical results of carbon ion radiotherapy at NIRS. J Radiat Res 48S:A1-A13
19. Sugane T, Baba M, Imai R et al (2009) Carbon ion radiotherapy for elderly patients 80 years and older with stage I non-small cell lung cancer. Lung Cancer 64:45-50
20. 11C]Methionine positron emission tomography and survival in patients with bone and soft tissue sarcomas treated by carbon ion radiotherapy. Clin Cancer Res 10:1764-1772
21. 11C-Methionine-PET for evaluation of carbon ion radiotherapy in patients with pelvic recurrence of rectal cancer. Mol Imaging Biol 10:374-380
22. 11C]gefitinib for imaging epidermal growth factor receptor tyrosine kinase with positron emission tomography. J Labelled Comp Radio-pharm 49:883-888
23. 11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase. Bioorg Med Chem Lett 16:4102-4106
24. 18F]-ZD1839 as a PET imaging agent for epidermal growth factors receptors. J Labelled Comp Radiopharm 46:s1
25. 18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 35:1089-1099
26. Ando K, Koike S, Fukuda N, Kanehira C (1984) Independent effect of a mixed-beam regimen of fast neutrons and gamma rays on a murine fibrosarcoma. Radiat Res 98:96-106
27. Ando K, Koike S, Ohira C et al (1999) Accelerated reoxygenation of a murine fibrosarcoma after carbon-ion radiation. Int J Radiat Biol 75:505-512
28. Koike S, Ando K, Oohira C et al (2002) Relative biological effectiveness of 290 MeV/u carbon ions for the growth delay of a radioresistant murine fibrosarcoma. J Radiat Res 43:247-255
29. Ando K, Koike S, Uzawa A et al (2005) Biological gain of carbon-ion radiotherapy for the early response of tumor growth delay and against early response of skin reaction in mice. J Radiat Res 46:51-57
30. Suzuki K, Inoue O, Hashimoto K, Yamasaki T, Kuchiki M, Tamate K (1985) Computer-controlled large scale production of high specific activity [11C]Ro 15-1788 for PET studies of benzodiazepine receptors. Int J Appl Radiat Isot 36:971-976
31. Takei M, Kida T, Suzuki K (2001) Sensitive measurement of positron emitters eluted from HPLC. Appl Radiat Isot 55:229-234
32. Elkind NB, Szentpetery Z, Apati A et al (2005) Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, gefitinib). Cancer Res 65:1770-1777
33. Mishani E, Abourbeh G, Jacobson O et al (2005) High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem 48:5337-5348
34. Pal A, Glekas A, Doubrovin M et al (2006) Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 8:262-277
35. Mishani E, Abourbeh G (2007) Cancer molecular imaging: radio-nuclide-based biomarkers of the epidermal growth factor receptor (EGFR). Curr Top Med Chem 7:1755-1772
36. Ghosh S, Liu XP, Zheng Y, Uckun FM (2001) Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents. Curr Cancer Drug Targets 1:129-140
37. Bianco R, Damiano V, Gelardi T, Daniele G, Ciardiello F, Tortora G (2007) Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. Curr Pharm Des 13:3358-3367
38. Press MF, Lenz HJ (2007) EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 67:2045-2075